Literature DB >> 11289330

Variations in serum levels of interleukin (IL)-1beta, IL-2, IL-6, and tumor necrosis factor-alpha during specific immunotherapy.

M De Amici1, F Puggioni, L Casali, R Alesina.   

Abstract

BACKGROUND: Cytokine production by T helper cells is essential for the induction and maintenance of allergic inflammation in the bronchial mucosa. According to recent views, specific immunotherapy (SIT) favors the differentiation of T lymphocytes into cells of the Th1 rather than those of the Th2 subset.
OBJECTIVE: To determine whether or not SIT induces a decrease in the inflammatory reaction by studying eventual variations in the serum levels of IL-1beta, IL-2, IL-6, and TNF-alpha in allergic subjects during SIT.
METHODS: Serum levels of IL-1beta, IL-2, IL-6, and TNF-alpha were determined before and after 3, 6, and 9 months of SIT by an immunoradiometric assay (IRMA) in 11 adults with perennial allergic asthma and/or rhinitis caused by house dust mites and in 6 nonatopic healthy volunteers.
RESULTS: Median serum IL-1beta and TNF-alpha levels of the patients were significantly higher at baseline than those of the controls and decreased during SIT to values similar to or lower (P < .01) after 6 months of SIT for TNF-alpha than those of the controls. Median serum IL-2, significantly lower at baseline than in the controls, increased during SIT to a level similar to that of the controls. Although the median values of IL-1beta and TNF-alpha in the patients tended to decrease and those of IL-2 to increase during SIT, the differences were not significant; the correlation coefficients (r) of the serum levels of IL-1beta IL-6, and TNF-alpha versus duration of SIT were negative, while that of IL-2 was positive.
CONCLUSIONS: Decreases in median serum IL-1beta and TNF-alpha levels during SIT, together with the increases in serum IL-2 and IL-6, compared with those of the controls furnish evidence supporting a reduction in the inflammatory response in the course of SIT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289330     DOI: 10.1016/S1081-1206(10)63304-2

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  6 in total

Review 1.  Immunotherapy in the age of anti-IgE.

Authors:  Ira Finegold
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

2.  Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T cell tolerance in children with allergic asthma.

Authors:  Chuang-Ming Wang; Chia-Bin Chang; Michael Wy Chan; Zhi-Hong Wen; Shu-Fen Wu
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

3.  Comparative study on the gastrointestinal- and immune- regulation functions of Hedysari Radix Paeparata Cum Melle and Astragali Radix Praeparata cum Melle in rats with spleen-qi deficiency, based on fuzzy matter-element analysis.

Authors:  Yugui Zhang; Jiangtao Niu; Shujuan Zhang; Xinlei Si; Tian-Tian Bian; Hongwei Wu; Donghui Li; Yujing Sun; Jing Jia; Erdan Xin; Xingke Yan; Yuefeng Li
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 4.  Allergic rhinitis in children : diagnosis and management strategies.

Authors:  William E Berger
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 5.  Immunological mechanisms in specific immunotherapy.

Authors:  Carsten B Schmidt-Weber; Kurt Blaser
Journal:  Springer Semin Immunopathol       Date:  2003-10-24

6.  Immunolocalization of NLRP3 Inflammasome in Normal Murine Airway Epithelium and Changes following Induction of Ovalbumin-Induced Airway Inflammation.

Authors:  Hai B Tran; Martin D Lewis; Lor Wai Tan; Susan E Lester; Leonie M Baker; Jia Ng; Monica A Hamilton-Bruce; Catherine L Hill; Simon A Koblar; Maureen Rischmueller; Richard E Ruffin; Peter J Wormald; Peter D Zalewski; Carol J Lang
Journal:  J Allergy (Cairo)       Date:  2012-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.